Treatment Recommendations for Osteosarcoma and Adult Soft Tissue Sarcomas

Overview

Journal Drugs

Specialty Pharmacology

Date 1994 Jan 1

PMID 7510623

Citations 14

Authors

P Picci

S Ferrari

G Bacci

F Gherlinzoni

Affiliations

Soon will be listed here.

Abstract

During the past 20 years, dramatic improvements have been obtained in the treatment of localised osteosarcoma of the extremities, both in the rates of disease-free survival and in quality of life. Twenty years ago 80 to 90% of the patients died, in spite of mutilating surgery, but now about 75% survive and avoid the necessity of amputation. This is due to the introduction of very effective combined treatments, mostly also using preoperative chemotherapy. One of the major issues is that of intensive preoperative chemotherapy, which improves both limb salvage and survival. A multidisciplinary approach is necessary to obtain good results. When the role of adjuvant or neoadjuvant chemotherapy is not accurately defined for soft tissue sarcomas, particular emphasis is given to the staging of the diseases and to the important role of local treatment in the survival of these patients. A combination of radiation therapy and surgery is strongly recommended.

Citing Articles

Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model.

Brozovich A, Lenna S, Brenner C, Serpelloni S, Paradiso F, McCulloch P ACS Biomater Sci Eng. 2024; 10(3):1646-1660.

PMID: 38350651 PMC: 10936525. DOI: 10.1021/acsbiomaterials.3c01266.

LINC00511 Promotes Osteosarcoma Tumorigenesis and Invasiveness through the miR-185-3p/E2F1 Axis.

Xu J, Chen G, Zhang Y, Huang Z, Cheng X, Gu H Biomed Res Int. 2020; 2020:1974506.

PMID: 32964019 PMC: 7501572. DOI: 10.1155/2020/1974506.

Tc-MIBI Scintigraphy for the Preoperative Assessment of Histological Response to Neoadjuvant Chemotherapy in Patients With Osteosarcoma: A Systematic Review and a Bivariate Meta-Analysis.

Wu F, Huang Y, Fang S, Huang X, Huang X, Zhang Z Front Oncol. 2020; 10:762.

PMID: 32528883 PMC: 7258398. DOI: 10.3389/fonc.2020.00762.

High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients.

Schuster A, Kager L, Reichardt P, Baumhoer D, Csoka M, Hecker-Nolting S Sarcoma. 2018; 2018:1632978.

PMID: 29853778 PMC: 5954899. DOI: 10.1155/2018/1632978.

Primary intraventricular osteosarcoma in a 3-year-old boy: report of a case and review of literature.

Boshrabadi A, Surakiazad M, Karimi Yarandi K, Amirjamshidi A Childs Nerv Syst. 2017; 33(8):1389-1394.

PMID: 28623518 DOI: 10.1007/s00381-017-3450-x.

References

Spanier S, Shuster J, Vander Griend R . The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am. 1990; 72(5):643-53. View

Ochs J, Freeman A, Douglass Jr H, Higby D, Mindell E, Sinks L . cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep. 1978; 62(2):239-45. View

Link M, Goorin A, Miser A, Green A, Pratt C, Belasco J . The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314(25):1600-6. DOI: 10.1056/NEJM198606193142502. View

RUSSELL W, SUTOW W, Martin R . Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol. 1977; 67(5):427-35. DOI: 10.1093/ajcp/67.5.427. View

Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C . The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer. 1981; 48(7):1569-81. DOI: 10.1002/1097-0142(19811001)48:7<1569::aid-cncr2820480717>3.0.co;2-x. View

Powers B, Withrow S, Thrall D, Straw R, LaRue S, Page R . Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer. 1991; 67(1):126-34. DOI: 10.1002/1097-0142(19910101)67:1<126::aid-cncr2820670123>3.0.co;2-7. View

Saeter G, Alvegard T, Elomaa I, Stenwig A, Holmstrom T, SOLHEIM O . Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991; 9(10):1766-75. DOI: 10.1200/JCO.1991.9.10.1766. View

Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R . Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and.... Cancer. 1990; 65(11):2539-53. DOI: 10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m. View

Mouridsen H, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder J . Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987; 23(10):1477-83. DOI: 10.1016/0277-5379(87)90089-7. View

10.

Wang J, Cortes E, Sinks L, HOLLAND J . Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer. 1971; 28(4):837-43. DOI: 10.1002/1097-0142(1971)28:4<837::aid-cncr2820280406>3.0.co;2-4. View

11.

Picci P, Capanna R, Bacci G, Mercuri M, Biagini R, Ruggieri P . Margins, necrosis and local recurrence after conservative surgery in osteosarcoma. Chir Organi Mov. 1990; 75(1 Suppl):82-5. View

12.

Jaffe N, Paed D, Farber S, Traggis D, Geiser C, Kim B . Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer. 1973; 31(6):1367-73. DOI: 10.1002/1097-0142(197306)31:6<1367::aid-cncr2820310611>3.0.co;2-6. View

13.

Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A . Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993; 72(11):3227-38. DOI: 10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c. View

14.

Suit H, Mankin H, Wood W, Gebhardt M, Harmon D, Rosenberg A . Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol. 1988; 6(5):854-62. DOI: 10.1200/JCO.1988.6.5.854. View

15.

La Vecchia C, Decarli A . Trends in cancer mortality in Italy, 1955-1978. Tumori. 1985; 71(3):201-18. DOI: 10.1177/030089168507100301. View

16.

Cortes E, HOLLAND J, Wang J, Sinks L, Blom J, Senn H . Amputation and adriamycin in primary osteosarcoma. N Engl J Med. 1974; 291(19):998-1000. DOI: 10.1056/NEJM197411072911903. View

17.

Gasparini M, Rouesse J, van Oosterom A, Wagener T, Somers R, Russel J . Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer Treat Rep. 1985; 69(2):211-3. View

18.

Potter D, Glenn J, Kinsella T, Glatstein E, Lack E, Restrepo C . Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol. 1985; 3(3):353-66. DOI: 10.1200/JCO.1985.3.3.353. View

19.

Gherlinzoni F, Bacci G, Picci P, Capanna R, Calderoni P, Lorenzi E . A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations. J Clin Oncol. 1986; 4(4):552-8. DOI: 10.1200/JCO.1986.4.4.552. View

20.

Toma S, Palumbo R, Sogno G, Venturino A, Santi L . Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. Ann Oncol. 1992; 3 Suppl 2:S119-23. DOI: 10.1093/annonc/3.suppl_2.s119. View